Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00025233 · OUTCOME

Progression-free Survival Greater Than 6 Months

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
90% Confidence Interval
Time frame
Every other 3-week treatment cycle for 6 months

What was measured

Whether or not the patient survived progression-free for at least 6 months.

Analysis population: Eligible and Treated Patients

Groups in this outcome

Bevacizumab

Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bevacizumab46

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Bevacizumab23.9Not reported14.036.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        14.0
        upper Limit
        36.5
        value
        23.9
denoms
  1. counts
    1. group Id
      OG000
      value
      46
    units
    Participants
description
Whether or not the patient survived progression-free for at least 6 months.
dispersion Type
90% Confidence Interval
groups
  1. description
    Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy
    id
    OG000
    title
    Bevacizumab
param Type
NUMBER
population Description
Eligible and Treated Patients
reporting Status
POSTED
time Frame
Every other 3-week treatment cycle for 6 months
title
Progression-free Survival Greater Than 6 Months
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice